10.07.2015 Views

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

220-Dictionary of Pharmaceutical Medicine, 2nd Edition-Gerhard Nahler Annette Mollet-3211898352-S

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

13bacterium Any <strong>of</strong> a large group <strong>of</strong> microscopic, single-cell organismswith a very simple cell structure; some manufacture their own foodfrom inorganic precursors alone, some live as parasites on otherorganisms, and some live on decaying matter.balanced study Trial in which numbers <strong>of</strong> patients and their characteristicsare equally distributed between groups e.g. similar number<strong>of</strong> males/females, above 65 years a.s.o.; → see also stratification.bar chart → see gantt chart.bar code Codification system using a number <strong>of</strong> vertical black linesthe relative widths <strong>of</strong> which encode a specific information; usedalso for automated form reading by optical mark recognition;→ see also code.baseline variables Characteristics <strong>of</strong> a patient and <strong>of</strong> his/her diseasemeasured before the start (as soon as measurements are constant)<strong>of</strong> protocol treatment (baseline period); → see also runin-phase;b.v. are important for the evaluation <strong>of</strong> the results <strong>of</strong> aclinical trial to avoid regression to the mean or learning effects;→ see also placebo effect.batch syn. lot; EC (IV): “a defined quantity <strong>of</strong> starting material, packagingmaterial or product processed in one process or series <strong>of</strong>processes so that it could be expected to be homogeneous”; FDA:“specific quantity <strong>of</strong> a drug or other material that is intended tohave uniform character and quality, within specific limits, and isproduced according to a single manufacturing order during thesame cycle <strong>of</strong> manufacture”; for stability testing batches shouldbe selected at random, with not less than 3 batches to be takenfor assessment <strong>of</strong> batch-to-batch variability; in order to be GMPcomplianta batch must have a minimal size <strong>of</strong> 100,000 units (e.g.,vials); → see also batch documentation, lot.batch documentation EC: set <strong>of</strong> documents making possible to tracethe history <strong>of</strong> the manufacture <strong>of</strong> a batch; b.d. needs to be retainedfor at least 1 year after the expiry date <strong>of</strong> the batch to which it relatesor at least 5 years after the certification, whichever is longer;samples <strong>of</strong> each batch must be retained for at least 1 year after theexpiry date, samples <strong>of</strong> starting materials (other than solvents,gases and water) used must be retained for at least 2 years after therelease <strong>of</strong> the product; → see also finished product.batch number EC (IV): “a distinctive combination <strong>of</strong> numbers and/or letters which specifically identifies a batch”; NLN: “a designationgiven by the manufacturer to a batch for the purpose <strong>of</strong> itsidentification”.Bayesian adverse reaction diagnostic instrument (BARDI) Bayesianbased approach for assessing drug-induced illness; the goal isbay

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!